Patient

no.

Age/Sex

Underlying

disease

Status at

transplantation

Conditioning

Stem cell source

GVHD prophylaxis

Prophylactic

antibiotics

1

49/male

ATLL

CR1

TBI (12 Gy) + CY

UR-BM

Tacrolimus + sMTX

LVFX

2

44/male

AML

CR1

Flu + BU + TBI (2 Gy)

UR-BM

Tacrolimus + sMTX

-

3

20/male

ALL

CR1

TBI (12 Gy) + CY

Rel-PB

Ciclosporin + sMTX

TFLX

4

45/female

ALL

CR2

TBI (12 Gy) + CA + CY

UR-CB

Tacrolimus + sMTX

LVFX

5

44/male

LBL

PR1

TBI (12 Gy) + CA + CY

UR-CB

Tacrolimus + sMTX

LVFX

6

44/male

MDS

CR1

TBI (12 Gy) + CA + CY

UR-CB

Tacrolimus + sMTX

LVFX

7

62/male

ALL

CR2

Flu + Mel + TBI (4 Gy)

UR-CB

Tacrolimus + sMTX

LVFX

8

24/male

AML

CR2

TBI (12 Gy) + CY

UR-BM

Tacrolimus + sMTX

LVFX

9

46/male

ATLL

CR1

TBI (12 Gy) + CY

Rel-PB

Ciclosporin + sMTX

CPFX

10

19/male

ALCL

primary refractory

TBI (12 Gy) + CY

UR-BM

Tacrolimus + sMTX

LVFX